Answers are grounded in this paper and cite their sources.
Purpose of review Polypharmacy with psychotropic drugs has a frequent occurrence in the treatment of psychiatric diseases. Nevertheless, there are still substantial deficits in established knowledge about combination and augmentation therapies. Recent findings Results of recent studies investigating the frequency of combination therapy with antipsychotics showed that up to 50% of patients diagnosed with schizophrenia received antipsychotic combination therapy and 90% were treated with antipsychotics augmented by psychotropic agents of different classes. Similar results were found in patients diagnosed with major depression. Only a few studies investigated combination or augmentation treatment regimes in large controlled trials. Summary Polypharmacy is generally not recommended. There may be reasons, however, for using combination or augmentation therapy, even in the absence of controlled studies. These reasons might be partial or nonresponse, acute treatment or switching processes. Combining different antipsychotics or antidepressants may lead to enlarged receptor binding profiles and the augmentation of antipsychotics by anticonvulsants in bipolar disorders is recommended as first-line treatment. Nevertheless, all possible benefits have to be weighed against increased risks for adverse effects and different alternatives to combination or augmentation therapy have to be considered. Other options might be monotherapy with different available psychotropic agents, as well as high-dose monotherapy with one agent. Despite that, a relevant number of patients might respond, if they are treated longer on one agent. Therefore, at present, using polypharmacy as treatment for psychiatric diseases might best be guided by individual clinical characteristics.
No takes yet. Share an insight, caveat, or question.
Karow et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: